ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Madrid, MD, ESP:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Madrid, Spain and 164 other locations

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Pozuelo De Alarcón, Madrid, Spain and 33 other locations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...

Enrolling
Leukemia, Myeloid, Acute
Drug: Bleximenib
Drug: Daunorubicin or Idarubicin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 30 other locations

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856...

Active, not recruiting
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Drug: VEN
Drug: AZA

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 19 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: MBG453
Drug: Venetoclax

Phase 2

Novartis
Novartis

Madrid, Spain and 27 other locations

or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...

Enrolling
Acute Myeloid Leukemia
Drug: Quizartinib
Drug: Cytarabine

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 36 other locations

when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Valencia, Valenciana, Spain and 108 other locations

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

Madrid, Spain and 73 other locations

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: azacitidine
Drug: gilteritinib

Phase 3

Astellas
Astellas

Madrid, Spain and 110 other locations

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Madrid, Spain and 160 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems